TP53 and sarcoma: In their report, they highlighted two main findings: firstly, sarcomas are mostly characterized by copy number alterations and low somatic mutation burden, whereas only a few genes (TP53, ATRX, and RB1) are repetitively mutated in all sarcoma types, and secondly, molecular subtypes related to patient outcome could be defined based on genomic driver pathways.